Centessa Pharmaceuticals (CNTA) Return on Sales (2022 - 2025)
Historic Return on Sales for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to 16.18%.
- Centessa Pharmaceuticals' Return on Sales fell 789300.0% to 16.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.18%, marking a year-over-year decrease of 789300.0%. This contributed to the annual value of 22.05% for FY2023, which is N/A changed from last year.
- As of Q3 2025, Centessa Pharmaceuticals' Return on Sales stood at 16.18%, which was down 789300.0% from 15.36% recorded in Q2 2025.
- Centessa Pharmaceuticals' Return on Sales' 5-year high stood at 62.75% during Q3 2024, with a 5-year trough of 16.18% in Q3 2025.
- Over the past 4 years, Centessa Pharmaceuticals' median Return on Sales value was 18.95% (recorded in 2022), while the average stood at 18.78%.
- Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 475400bps in 2024, then plummeted by -789300bps in 2025.
- Centessa Pharmaceuticals' Return on Sales (Quarter) stood at 19.6% in 2022, then decreased by -27bps to 14.33% in 2023, then soared by 338bps to 62.75% in 2024, then crashed by -126bps to 16.18% in 2025.
- Its Return on Sales was 16.18% in Q3 2025, compared to 15.36% in Q2 2025 and 1.74% in Q1 2025.